On 28th September there was a two-hour public hearing on the GKV Financial Stabilisation Act. There ...
Read moreWe investigate Single Technology Appraisals (STAs) conducted by NICE, comparing outcomes for monothe...
Read moreWe look at whether payers are willing to pay for innovative gene therapies & CAR-Ts and the impact o...
Read moreOur Market Access analysts summarise the EUnetHTA draft scoping process and provide considerations a...
Read moreThe EUNetHTA recently published its draft scoping guidance which outlines how the contrasting decisi...
Read moreNICE have been clear that this framework should not be interpreted as minimum standards for real-wor...
Read moreEUnetHTA and the EU Joint HTA Process EUnetHTA was established in 2006 to facilitate information sha...
Read moreIntroduction Achieving access to patients for innovative treatments is becoming a significant challe...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreThrough the new fund, £340 million is to be made available to purchase promising, potentially life-...
Read more